Alamar Biosciences (NASDAQ: ALMR) reported second-quarter 2026 revenue of $29.4 million, an 82% increase from $16.2 million in the same period of 2025, driven primarily by a 147% year-over-year surge in consumable sales. The precision proteomics company also provided full-year 2026 revenue guidance of $116 million to $120 million, representing a 59% growth at the midpoint compared to the prior year and beating consensus analyst estimates of $113.259 million. Despite the strong top-line performance, the company reported a net loss of $13.2 million for the quarter, widening from a $7.0 million loss in Q2 2025, as operating expenses rose 89% to $31.2 million due to planned investments in headcount, infrastructure, and research and development capabilities.

Revenue Breakdown and Operational Highlights

The revenue growth was underpinned by robust demand across all segments. Consumable revenue jumped to $15.5 million from $6.3 million in the prior-year period, fueled by strong adoption of multiplex panels. Instrument revenue grew 35% to $7.8 million from $5.8 million, supported by continued new instrument placements. Services and other revenue increased 49% to $6.2 million from $4.1 million. Gross margin improved to 60% from 53% in the corresponding period last year, attributed to manufacturing efficiencies for consumables and a favorable shift in mix toward high-margin products.

Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences, stated that consumable revenue grew nearly 150% year-over-year. He highlighted recent launches of the eMTBR-tau assay and the Immune 340 Panel as key drivers strengthening the content menu and extending into new disease areas. The company also expanded its strategic partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures to deliver a combined dataset of more than 140,000 samples.

Profitability and Balance Sheet Position

While revenue surged, profitability remained elusive due to aggressive scaling. Operating expenses totaled $31.2 million, including $3.3 million in stock-based compensation, compared to $16.5 million and $0.7 million respectively in Q2 2025. The operating loss widened to $13.5 million from $7.9 million. Net loss stood at $13.2 million, or $0.22 per share, compared to $7.0 million, or $0.62 per share, in the prior-year period.

The company’s balance sheet remains strong, with cash, cash equivalents, short-term investments, and restricted cash totaling $256.3 million as of June 30, 2026. This represents a significant increase from the previous period, providing ample runway for continued R&D investments and commercial expansion. Total assets rose to $390.9 million from $139.9 million at the end of December 2025, reflecting both cash accumulation and growth in inventory and receivables.

What the Numbers Show

The divergence between accelerating revenue growth and expanding losses underscores Alamar Biosciences’ transition phase from product development to commercial scale-up. The 147% surge in consumable revenue suggests that initial instrument placements are successfully converting into recurring high-margin sales, a critical milestone for proteomics platforms. However, the 89% rise in operating expenses indicates that the company is prioritizing market penetration and capability building over immediate profitability. With gross margins improving to 60%, the operational leverage is beginning to take hold, but the path to net profitability will depend on sustaining this revenue momentum while controlling the trajectory of selling, general, and administrative costs.

Alamar Biosciences, Inc. (NASDAQ: ALMR) launched the NULISAseq Immune 340 Panel on July 28, 2026, introducing its broadest multiplexed immune profiling solution for translational research and drug development. The new panel allows researchers to measure approximately 340 immune-related proteins simultaneously from a single sample, addressing detection gaps in low-concentration biomarkers that signal disease before symptoms appear. This expansion builds on the company’s existing NULISAseq Inflammation Panel 250, aiming to accelerate biomarker discovery and strengthen therapy development across cancer, cardiovascular, metabolic, autoimmune diseases, and aging research.

The launch addresses significant challenges in detecting immune mediators such as cytokines, chemokines, and cell death pathway markers, which often circulate at fg/mL to sub-pg/mL concentrations. These levels are typically below the detection floor of conventional immunoassays, particularly in inflammaging—the chronic, low-grade inflammation associated with aging that drives risk for cardiovascular, metabolic, neurodegenerative, and cancer conditions. By capturing these previously invisible signals, Alamar seeks to provide deeper insights into the immune proteome.

Key Features of NULISAseq Immune 340

Dr. Yuling Luo, founder, chief executive officer and chair of Alamar Biosciences, stated that the immune system holds some of the earliest and most informative signals of disease, yet much of that biology has been out of reach. He noted that the NULISAseq Immune 340 provides an unprecedented view of immune activity, which he believes will accelerate biomarker discovery and advance the company’s mission of detecting disease earlier.

Industry Validation

Bailin Zhang, PhD, head of exploratory biomarkers in the Translational Medicine Unit at Sanofi, highlighted the panel’s distinctive combination of breadth and sensitivity. Zhang explained that many proteins relevant to immune mechanisms of action, resistance, and toxicity have historically been undetectable in blood. He added that accessing these markers alongside canonical ones in one multiplexed run opens new possibilities for biomarker discovery and patient stratification in drug development.

What the Numbers Show

The expansion from the 250-protein Inflammation Panel to the 340-protein Immune Panel represents a 36% increase in measurable targets. This growth reflects Alamar’s strategy to capture broader pathway crosstalk and feedback loops rather than isolated protein signals. The ability to detect sub-pg/mL concentrations differentiates the offering from conventional immunoassays, potentially reducing the need for multiple testing platforms in early-stage research. This integration could streamline workflows for pharmaceutical partners seeking comprehensive immune landscape profiles from limited sample volumes.